Efficacy and Safety of Apatinib in Patients with Recurrent Uterine Malignancy: a Prospective, Single-Center, Single-Arm, Phase 2 Study.
ANNALS OF TRANSLATIONAL MEDICINE（2023）
Key words
Apatinib,uterine malignancy,endometrial cancer (EC),uterine sarcoma (US),vascular endothelial growth factor receptor,tyrosine kinase inhibitor (VEGFR,TKI)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined